A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia

Baccarani, Michele; Gugliotta, Gabriele; Castagnetti, Fausto; Soverini, Simona; Rosti, Gianantonio

doi:10.1007/978-3-319-33198-0_4

Cited by 9 publications

(9 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even if a patient is not in acute distress, hospital admission for monitoring by the hematology/oncology service is warranted as these patients are at high risk for acute vascular crisis. Long-term therapy involves daily TKI with the goal of maintaining remission [9]. …”

Section: Discussionmentioning

confidence: 99%

The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia

Minckler

Conser

Figueroa

et al. 2017

Case Reports in Emergency Medicine

View full text Add to dashboard Cite

Priapism is defined as an erection that persists beyond four hours, lasting beyond or unrelated to sexual stimulation (Salonia et al., 2014). Because the risk of ischemic damage and impotence is high with priapism (35%), management guidelines are directed towards rapid treatment of this condition (Salonia et al., 2014). This report describes the rare case of an 18-year-old male who presented to the Emergency Department (ED) three times with recurrent and worsening episodes of sustained penile erections. On the patient's third visit, he presented with priapism of greater than six-hour duration that was found to be the result of chronic myeloid leukemia. Clinician awareness of the diagnostic semantics and differential diagnosis surrounding priapism is pivotal in its urgent management.

show abstract

Section: Discussionmentioning

confidence: 99%

The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia

Minckler

Conser

Figueroa

et al. 2017

Case Reports in Emergency Medicine

View full text Add to dashboard Cite

show abstract

“…BCR-ABL1 IS ≤10% at 3 months was defined as the EMR [7,8]. Baccarani M et al [9] and Jain P et al [10] presented that the measuring BCR-ABL1 IS at 3 months was the only factor to predict the outcome. Furthermore, the NCCN guidelines recommended that the patients with EMR failure at 3 months of imatinib therapy switched to the other TKIs for the maximum benefit [2].…”

Section: Ivyspringmentioning

confidence: 99%

BCR-ABL1 transcript decline ratio combined BCR-ABL1^IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

Cai

Jia

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Purpose: The early BCR-ABL1 reduction had the prognostic impact of the chronic-phase chronic myeloid leukemia (CML-CP) patients. This study was to find a more precise early prognosis index at 3 months in the patients with newly diagnosed CML-CP, especially for the patients with BCR-ABL1 IS >10%. Methods: We retrospectively analyzed the data of 79 newly diagnosed CML-CP patients from October 2013 to April 2017. All patients took imatinib regularly and continuously and monitored BCR-ABL1 transcript level at baseline and 3, 6, 9, 12, 18 months after starting imatinib treatment. Results: Among the 44(55.7%) patients with BCR/ABL1 IS ≤10% at 3 months after imatinib treatment, 12(27.3%) cases did not achieve major molecular response (MMR) at 12 months, and 7(14.9%) patients with the halving time BCR-ABL1 transcript ≤40 days failed to achieve MMR at 12 months. However, approximately twenty-six percent of the patients with BCR-ABL1 IS >10% still obtained MMR. Moreover, the patients with BCR-ABL1 IS ≤10% and halving time ≤40 days had a significantly better MMR than that of the patients with the BCR-ABL1 IS ≤10% and halving time >40 days (88.6% versus 11.1%, P <0.001). However, the patients with the BCR-ABL1 IS >10% and halving time >40 days rarely achieved MMR at 12 months. Conclusion: These data indicated that the halving time of BCR-ABL1 transcript was also an important prognostic factor as that of the BCR-ABL1 IS. Combined observations of these two prognosis indexes are more accurate predictor for the long-term molecular response, especially for the CML-CP patients with BCR-ABL1 IS >10%, and which is helpful for TKI switching as early as possible to improve patients' survival and reduce drug costs.

show abstract

“…However, with the introduction of imatinib, a breakpoint cluster region-abelson gene tyrosine kinase inhibitor, an anticancer agent known to significantly improve clinical outcome and reduce morbidity and mortality in these patients, their quality of life has been reported in various studies to increase markedly (1)(2)(3). This makes this drug a first-line therapy among other tyrosine kinase inhibitors (4). However, to ensure quality and durable remission, it is necessary to emphasize adherence to this drug and prevent cancer progression (1,2).…”

Section: Introductionmentioning

confidence: 99%

Challenges to Care and Medication Adherence of Patients With Chronic Myeloid Leukemia in a Resource Limited Setting

Bolarinwa

Olowookere

Owojuyigbe

et al. 2017

Journal of Patient Experience

View full text Add to dashboard Cite

The factors related to care of patients with chronic myeloid leukemia (CML) often affects treatment outcome. We examined adherence to medication and other challenges to care in our patients on treatment of CML. This qualitative study involved in-depth interviews of 20 patients with CML receiving free imatinib (Glivec) from the Glivec International Patients’ Assistance Program. Data collected were thematically analyzed. Findings revealed that despite free drug assistance, there was relative lack of awareness resulting in inappropriate health-seeking behavior. The challenges cut across situations such as poverty, fear of the sustenance of the compassionate drug program, and living far away from the clinic. Forgetfulness was reported as the cause of poor adherence in this study. Suggested solutions include increasing community awareness, ensuring sustainability of the program and establishing more treatment centers nationwide. Strategies such as reminders and patents’ support will improve drug adherence among this cohort.

show abstract

A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia

Cited by 9 publications

References 118 publications

The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia

The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia

BCR-ABL1 transcript decline ratio combined BCR-ABL1^IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

Challenges to Care and Medication Adherence of Patients With Chronic Myeloid Leukemia in a Resource Limited Setting

Contact Info

Product

Resources

About

A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia

Cited by 9 publications

References 118 publications

The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia

The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia

BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

Challenges to Care and Medication Adherence of Patients With Chronic Myeloid Leukemia in a Resource Limited Setting

Contact Info

Product

Resources

About

BCR-ABL1 transcript decline ratio combined BCR-ABL1^IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia